SCHEDULE OF CHANGES IN INVESTMENT (Details) - USD ($) |
12 Months Ended | |
|---|---|---|
Jul. 31, 2026 |
Jul. 31, 2025 |
|
| Restructuring Cost and Reserve [Line Items] | ||
| Funding | $ 377,000 | $ 330,000 |
| Share of losses | (263,477) | (224,212) |
| BC Therapeutics Inc [Member] | ||
| Restructuring Cost and Reserve [Line Items] | ||
| Beginning balance | 524,278 | |
| Funding | 377,000 | |
| BC Therapeutics Option | 193,829 | |
| Change in fair value during the period | (101,602) | |
| Share of losses | (263,477) | |
| Ending balance | $ 730,028 | $ 524,278 |
| X | ||||||||||
- Definition Gain loss on derivative instruments not designated as hedging instruments. No definition available.
|
| X | ||||||||||
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow associated with the purchase of all investments (debt, security, other) during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|